Expiry of Semaglutide Patent in India
The expiration of the patent for semaglutide, the active ingredient in Novo Nordisk’s 'weight-loss' drugs Ozempic and Wegovy, marks a notable shift in public health and the Indian pharmaceutical landscape.
Public Health Implications
- Non-communicable diseases are now a major concern in India, impacting economic productivity.
- Obesity-related costs were nearly 1% of GDP in 2019 and are projected to increase.
- Changing diets and lifestyles are affecting India's metabolic health, not just in urban areas but also in smaller towns and rural regions.
Role of GLP-1 Therapies
- Globally, GLP-1 therapies have improved management of type-2 diabetes and obesity by regulating blood sugar and reducing appetite.
- In India, semaglutide sales have increased, indicating strong demand despite affordability issues.
Impact of Patent Expiry
The entry of Indian manufacturers could lower prices of generic semaglutide by 70-90%, enhancing affordability and access.
Factors Influencing GLP-1 Therapy Adoption
- Affordability: Lower prices will make treatments accessible to more patients.
- Accessibility: Distribution networks can expand availability beyond urban hospitals.
- Availability: A robust supply chain will ensure the availability and continuity of care.
Healthcare System Impact
- GLP-1 therapies could integrate new patients into formal healthcare, helping diagnose comorbidities early.
- Obesity's impact on women's reproductive health, including PCOS and infertility, can be mitigated through improved metabolic stability.
Broader Implications
- GLP-1 therapies require clinical supervision and can reduce socio-economic costs related to obesity.
- Broader preventive measures such as awareness, nutrition, and physical activity are essential alongside medication.
- For Indian pharma, this represents an opportunity to advance in quality standards, doctor education, and ethical communication.
The expiration of the patent opens doors for Indian pharma to lead in affordable generics and advanced therapies, signaling a new beginning for healthcare in India.
